NCT02588105 - Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

September 13, 2019

Study Completion Date

July 26, 2022

Conditions

Advanced Solid Tumours

Interventions

DRUG

AZD0156

All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.

DRUG

Olaparib

Module 1 combination with olaparib

DRUG

irinotecan

Module 2 combination with irinotecan/FOLFIRI

DRUG

Fluorouracil

Module 2 combination with irinotecan/FOLFIRI

DRUG

Folinic Acid

Module 2 combination with irinotecan/FOLFIRI

Trial Locations (5)

Research Site, New York

Research Site, Aurora

Research Site, Seoul

Research Site, Barcelona

Research Site, Manchester